The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)—Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab

SIMPLE SUMMARY: Although taxane-trastuzumab-pertuzumab combinations in the first-line treatment setting significantly improved clinical outcomes in patients with Human Epidermal growth factor Receptor 2 positive (HER2+) advanced breast cancer (aBC), their clinical efficacy is highly heterogeneous, a...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Cancers (Basel)
Главные авторы: Ligorio, Francesca, Fucà, Giovanni, Zattarin, Emma, Lobefaro, Riccardo, Zambelli, Luca, Leporati, Rita, Rea, Carmen, Mariani, Gabriella, Bianchi, Giulia V., Capri, Giuseppe, de Braud, Filippo, Vernieri, Claudio
Формат: Artigo
Язык:Inglês
Опубликовано: MDPI 2021
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC8073809/
https://ncbi.nlm.nih.gov/pubmed/33921727
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13081964
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы